Maxim Group analyst Jason McCarthy maintained a Buy rating on OncoSec Medical (NASDAQ: ONCS) today and set a price target of $5. The company’s shares opened today at $1.38.
McCarthy commented:
“OncoSec provided an update on upcoming milestones as we move into 2H18, which in our view should be busy (i.e. catalysts) for the company: data in melanoma and triple negative breast cancer (TNBC); initiation of new combination studies of TAVO + checkpoint in TNBC, melanoma and H&N; and expansion of TAVO and novel immune-stimulating DNA-based candidates (see below). As important to focus on is the data presented in Pharmaceuticals (private) and how that could be a positive for OncoSec.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 11.0% and a 39.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, SELLAS Life Sciences Group Inc, and ContraVir Pharmaceuticals Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for OncoSec Medical with a $4.50 average price target, implying a 226.1% upside from current levels. In a report issued on June 14, H.C. Wainwright also reiterated a Buy rating on the stock with a $4 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $2.95 and a one-year low of $0.88. Currently, OncoSec Medical has an average volume of 916.1K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OncoSec Medical, Inc. engages in the design and commercialize medical products for the treatment of cancer. It involves in the discovery and development of novel immunotherapeutic products to improve treatment options for patients and physicians, which intends to treat oncology indications.
